In the short term the investigators hope to gain an improved understanding of the impact of residual beta cell function on hypoglycemic risk and treatment response in patients with type 2 diabetes. In the longer term the availability of a predictive biomarker for treatment response and hypoglycaemia risk would enable improved management of patients with insulin-treated diabetes.